Review of AENEAS Trial and Similar Agents
Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.
EGFR-Targeted TKIs in NSCLC and Cost
Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.
Impact of Payers on the Costs of Drugs
Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.
Personalized Therapies Based on Innovation and Affordability
Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.
Role of Financial Toxicity on Treatment Decisions
Experts in various specialties of oncology management share their insights on the role of financial toxicity on making treatment decisions for patients.
Definition of Financial Toxicity
Jack West, MD, Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, provide a definition for financial toxicity.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512